Venture capital firm

Aditum Bio

A biotech venture capital firm that develops drug candidates through to clinical trials

Write a review

Biotech

Visit Website Get introducedRequest an introduction Write a Review

Own this listing? Claim it

TrustList summary

Aditum Bio describes itself as a biotech venture capital firm built to translate scientific discoveries into new medicines. Rather than backing companies across the full life of drug development, it says it concentrates specifically on the translation phase, identifying and advancing drug candidates into the clinic. The firm was launched by a former chief executive of Novartis, Joe Jimenez, together with Dr Mark Fishman, formerly president of the Novartis Institutes for BioMedical Research; the site presents their scientific and operating experience as the basis for how candidates are selected. Aditum Bio says its model allows rapid company formation, planning and execution, with the aim of improving outcomes for patients and generating returns for its investors. The site does not name specific portfolio companies or say where the firm is based.

Summary written by TrustList from the business's own published information, Sep 2026.

Categories & features

Biotech

Rankings

Aditum Bio is ranked on 1 TrustList ranking at #18.

Every ranking orders its listings by their reviews, how complete the profile is and the Trust Score. Aditum Bio has no reviews yet and 3 of the 10 profile details we look for. Where no listing on a page has been reviewed, the order follows the profiles alone.

Venture capital firm · 1 ranking

#18of 79
Biotech investors
Of the top 65 here, 22 also cover healthtech and 17 also cover science; 14 also work in Boston and 13 also work in San Francisco.
Behind 20/20 HealthCare Partners, ahead of Advent France Biotechnology.

As of 2026-11-02. Organic ranks only; sponsored placements are never ranks. How TrustList ranks